These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 30722031)

  • 1. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
    Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
    Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy for renal cell carcinoma - current status].
    Grimm MO; Foller S
    Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.
    Perego G; Barzaghi P; Vavassori I; Petrelli F
    Med Oncol; 2020 Aug; 37(9):81. PubMed ID: 32767163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal management of metastatic renal cell carcinoma: current status.
    Escudier B; Albiges L; Sonpavde G
    Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
    Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
    Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Gill DM; Hahn AW; Hale P; Maughan BL
    Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in treatment of metastatic renal cell carcinoma.
    Gong J; Gerendash B; Dizman N; Khan A; Pal SK
    Curr Opin Urol; 2016 Sep; 26(5):439-46. PubMed ID: 27467136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.
    Labriola MK; Batich KA; Zhu J; McNamara MA; Harrison MR; Armstrong AJ; George DJ; Zhang T
    Clin Genitourin Cancer; 2019 Jun; 17(3):e513-e521. PubMed ID: 30858035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
    Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
    BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management of metastatic renal cell carcinoma: evolving new therapies.
    Kumar R; Kapoor A
    Curr Opin Support Palliat Care; 2017 Sep; 11(3):231-237. PubMed ID: 28590313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Afriansyah A; Hamid AR; Mochtar CA; Umbas R
    Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
    Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
    Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
    Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options.
    Loo V; Salgia M; Bergerot P; Philip EJ; Pal SK
    Target Oncol; 2019 Dec; 14(6):639-645. PubMed ID: 31595385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
    Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
    Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma].
    Miller K; Bergmann L; Doehn C; Gschwend J; Keilholz U
    Aktuelle Urol; 2017 Feb; 48(1):72-78. PubMed ID: 28403496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
    Gill DM; Agarwal N; Vaishampayan U
    Am Soc Clin Oncol Educ Book; 2017; 37():319-329. PubMed ID: 28561652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.
    Ornstein MC; Wood LS; Hobbs BP; Allman KD; Martin A; Bevan M; Gilligan TD; Garcia JA; Rini BI
    J Immunother Cancer; 2019 May; 7(1):127. PubMed ID: 31097024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.